{"id":6287,"date":"2019-12-09T10:15:40","date_gmt":"2019-12-09T09:15:40","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/identifizierung-neuer-zielmolekuele-fuer-asthma\/"},"modified":"2020-09-25T07:54:58","modified_gmt":"2020-09-25T05:54:58","slug":"identifizierung-neuer-zielmolekuele-fuer-asthma","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/identifizierung-neuer-zielmolekuele-fuer-asthma\/","title":{"rendered":"Identification of new asthma targets"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Identification of new asthma targets<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]Pieris Pharmaceuticals is cooperating with the University of
\nPittsburgh[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]December 2019[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Pieris Pharmaceuticals, Inc., announced a research collaboration between the Company and two labs of the University of Pittsburgh on November 15. Pieris, a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin\u00ae technology platform for respiratory diseases, cancer, and other indications, will join forces with Professors Sally Wenzel, MD, and Anuradha Ray, PhD, to focus on comprehensive immune phenotyping of severe asthmatic patients. Key objectives of the multi-year collaboration include patient stratification strategies for more streamlined development of therapeutic interventions as well as identifying and validating novel asthma targets.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”6283″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]The Lungs[\/vc_column_text][vc_single_image image=”6285″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Stephen S. Yoder<\/strong>, CEO, Pieris Pharmaceuticals Inc.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text css=”.vc_custom_1591733418411{margin-bottom: 22px !important;}”]\u201cWenzel and Ray have been invaluable advisors to Pieris over the last several years, and I am pleased that we can strengthen our relationship with this collaborative research component in our commitment to expand our pipeline of proprietary respiratory therapeutics,\u201d said Stephen S. Yoder, President and Chief Executive Officer of Pieris. \u201cEmerging research from their labs demonstrates the power of combining bench-to-bedside research with big data mining, to better understand how to address the as of yet unmet needs of severe asthma patients.\u201d[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n